Lantidra’s First-Cycle Complete Response Letter Centered On Inspection And Product Quality Issues

 
• By Sue Sutter
  
Drug Review Profile: Lantidra
CellTrans had to address a host of product quality deficiencies before approval. • Source: Pink Sheet/Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Drug Review Profiles

More from Product Reviews